RenovoRx Secures Japanese Patent for Targeted Drug Delivery System
Event summary
- RenovoRx received a Notice of Allowance from the Japan Patent Office for patent application JP 2024-559262, covering its RenovoCath device’s method and apparatus for targeted drug delivery.
- The patent protects RenovoRx’s dual-occlusion catheter-based system utilizing the vasa vasorum for targeted drug infusion.
- RenovoRx now holds 19 issued or allowed patents and has 14 pending, supporting the commercialization of RenovoCath.
- RenovoRx generated approximately $1.1 million in RenovoCath sales in its first full year of commercial efforts.
The big picture
Securing patent protection in Japan, a key market for medical devices, strengthens RenovoRx’s global IP position and underscores the potential of its Trans-Arterial Micro-Perfusion (TAMP) platform. While the $1.1 million in sales demonstrates initial commercial traction, the company’s long-term success hinges on demonstrating clinical efficacy and navigating the complexities of regulatory approval and market access in a competitive landscape.
What we're watching
- Market Access
- The speed with which RenovoRx can establish distribution channels and secure reimbursement in Japan will be critical to realizing the patent’s value.
- Clinical Data
- The success of the ongoing Phase III TIGeR-PaC trial evaluating IAG will significantly impact the commercial viability of the RenovoCath platform.
- Competitive Landscape
- The emergence of competing targeted drug delivery technologies could erode RenovoRx’s first-mover advantage and necessitate further innovation.
Related topics